<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536028</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1746</org_study_id>
    <secondary_id>2005-004965-40</secondary_id>
    <nct_id>NCT01536028</nct_id>
  </id_info>
  <brief_title>Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blind, Randomised, Four-Period Crossover Trial Comparing the Pharmacodynamics and Pharmacokinetics After Single Dose of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Insulin Aspart in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics
      and pharmacokinetics after a single dose of biphasic insulin aspart 30, biphasic insulin
      aspart 50, biphasic insulin aspart 70 and insulin aspart in subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum GIR value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum GIR value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the GIR-curves</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration for insulin aspart (IAsp)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum IAsp concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of the IAsp profiles</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum drug concentration in NEFA (Nonesterified fatty acids)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to minimum plasma concentration, NEFA</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of the NEFA profiles</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic episodes</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IAsp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between</description>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_label>IAsp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between</description>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_label>IAsp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between</description>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_label>IAsp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between</description>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_label>IAsp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Serum C-peptide maximum 0.4 ng/mL

          -  Current basal bolus treatment with soluble human insulin, insulin lispro, insulin
             glulisine, NPH insulin, insulin detemir or insulin glargine

          -  BMI (Body Mass Index) maximum 32 kg/m^2

          -  HbA1c (glycosylated haemoglobin) maximum 9% based on analysis from central laboratory

          -  Non-smoker

        Exclusion Criteria:

          -  The receipt of any investigational drug within the last 30 days prior to this trial

          -  Total daily insulin dose at least 1.8 U/kg/day

          -  Current treatment with IAsp (insulin aspart) products

          -  A history of drug or alcohol abuse within the last 5 years

          -  Impaired hepatic function

          -  Impaired renal function

          -  Cardiac problems

          -  Severe, uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther. 2008 Dec;10(6):479-85. doi: 10.1089/dia.2008.0019.</citation>
    <PMID>19049377</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

